Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Change in Account Payables (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Change in Account Payables for 13 consecutive years, with $538000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Account Payables rose 344.55% to $538000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $759000.0, a 21.27% decrease, with the full-year FY2024 number at $750000.0, up 12400.0% from a year prior.
  • Change in Account Payables was $538000.0 for Q3 2025 at Theravance Biopharma, up from -$733000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $2.2 million in Q3 2022 to a low of -$3.8 million in Q4 2022.
  • A 5-year average of -$74000.0 and a median of $166000.0 in 2025 define the central range for Change in Account Payables.
  • Biggest YoY gain for Change in Account Payables was 344.55% in 2025; the steepest drop was 36550.0% in 2025.
  • Theravance Biopharma's Change in Account Payables stood at -$1.1 million in 2021, then tumbled by 250.61% to -$3.8 million in 2022, then skyrocketed by 126.63% to $1.0 million in 2023, then decreased by 21.36% to $788000.0 in 2024, then tumbled by 31.73% to $538000.0 in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Change in Account Payables are $538000.0 (Q3 2025), -$733000.0 (Q2 2025), and $166000.0 (Q1 2025).